The U.S. Food and Drug Administration approved Biogen’s aducanumab, the first drug to target an underlying cause of Alzheimer’s disease. The drug, to be sold under the brand Aduhelm, is the first new approval of an Alzheimer’s drug since 2003 and the only treatment designed to slow progression of the mind-robbing disease.
If you are not happy with the results below please do another search
50 search results for:
The U.S. Food and Drug Administration approved the expanded use of Alexion Pharmaceuticals Inc.’s Ultomiris (ravulizumab-cwvz) to include children (1 month of age and older) and adolescents with paroxysmal nocturnal hemoglobinuria (PNH).
Following huge success over the past 3.5 years, the allegro. accelerated learning and development model is adding a new program to its portfolio. The launch of allegro.EXCEL provides structured career development for senior medical writers to accelerate their career to scientific leadership positions in Ashfield Health.
United Therapeutics Corporation announced that the company is pursuing additional claims for trade secret misappropriation against Liquidia Technologies Inc. and a former United Therapeutics employee who later joined Liquidia as an executive.
U.S. regulators on June 7 approved Biogen Inc.’s aducanumab as the first treatment to attack a likely cause of Alzheimer’s disease despite controversy over whether the clinical evidence proves the drug works, sending the company’s shares soaring.
Safety concerns about Johnson & Johnson’s Covid-19 vaccine along with overall flagging demand for vaccinations have slowed its U.S. rollout to a crawl, leaving close to half of the 21 million doses produced for the United States sitting unused.
British life sciences company NetScientific Plc said on June 7 that one of the company’s subsidiaries entered an exclusive licensing agreement with AstraZeneca Plc to globally sell a Covid-19 test.
The United States had administered 301,638,578 doses of Covid-19 vaccines in the country and distributed 371,520,735 doses as of the morning of June 6, the U.S. Centers for Disease Control and Prevention said.
Novartis announced Phase II primary endpoint data showing the investigational, first-in-class, oral, targeted factor B inhibitor iptacopan reduced protein in the urine – an increasingly recognized surrogate marker correlating with progression to kidney failure – and showed promise in stabilizing kidney function in patients with IgA nephropathy (IgAN).
On June 5, the United States and the rest of the world marks a grim milestone – the 40th anniversary of the HIV epidemic. While the virus has taken the lives of an estimated 35 million people over the last 40 years, an end could be in sight as biopharma researchers continue to develop safe and effective new treatments, with an eye toward a potential cure.